Ponazuril

Ponazuril
Clinical data
Trade names	Marquis
AHFS/Drugs.com	FDA Professional Drug Information
Routes of; administration	Oral
ATCvet code	QP51AJ04 (WHO) ;
Legal status
Legal status	US: ℞-only ; Veterinary use only;
Identifiers
	IUPAC name 1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione;
CAS Number	69004-04-2 ;
PubChem CID	3050408;
ChemSpider	2312474 ;
UNII	JPW84AS66U;
CompTox Dashboard (EPA)	DTXSID7048958 ;
ECHA InfoCard	100.157.907
Chemical and physical data
Formula	C18H14F3N3O6S
Molar mass	457.380 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F;
	InChI InChI=1S/C18H14F3N3O6S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)30-12-4-6-13(7-5-12)31(28,29)18(19,20)21/h3-9H,1-2H3,(H,22,25,26) ; Key:VBUNOIXRZNJNAD-UHFFFAOYSA-N ;
(what is this?) (verify)

Ponazuril (INN), sold by Merial, Inc.[1], now part of Boehringer Ingelheim[2], under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona.[3][4] More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.

References

"Merial Aquires LEGEND® and MARQUIS® | Boehringer Ingelheim". merial.com. Retrieved 2018-04-30.
"Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com". boehringer-ingelheim.com. Retrieved 2018-04-30.
Marquis FDA Professional Drug Information
MacKay, R. J.; Tanhauser, S. T.; Gillis, K. D.; Mayhew, I. G.; Kennedy, T. J. (2008). "Effect of intermittent oral administration of ponazuril on experimentalSarcocystis neuronainfection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Merial Aquires LEGEND® and MARQUIS® | Boehringer Ingelheim". merial.com. Retrieved 2018-04-30.

[2] "Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com". boehringer-ingelheim.com. Retrieved 2018-04-30.

[3] Marquis FDA Professional Drug Information

[4] MacKay, R. J.; Tanhauser, S. T.; Gillis, K. D.; Mayhew, I. G.; Kennedy, T. J. (2008). "Effect of intermittent oral administration of ponazuril on experimentalSarcocystis neuronainfection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.

Ponazuril

See also

References